Tempus AI

Tempus AI reported Q2 2026 (quarter ended June 30, 2026) total revenue of $382.5 million, up 22% year-over-year from $314.6 million. Diagnostics revenue was $289.3 million (up 20%), and Data and Applications revenue was $93.2 million (up 28%). GAAP gross profit rose 26% to $246.5 million. GAAP net income was $5.6 million (diluted EPS $0.03), compared with a net loss of $42.8 million in Q2 2025; the release notes this figure included $98.5 million in unrealized gains on marketable securities and $55.6 million of stock compensation and related payroll taxes. GAAP loss from operations was $75.9 million. Adjusted EBITDA was $8.0 million, compared with ($5.6 million) a year earlier. Operationally, Oncology volume grew 31% and MRD volume reached 9,000 tests (from 6,500 in the prior quarter, as stated in the release). Data Licensing (Insights) revenue rose 36%, and the company signed about $200 million in new Data and Applications licenses. The FDA approved the tumor-only xT CDx assay, and the company agreed to acquire Personalis for $16.25 per share (about $1.5 billion enterprise value), expected to close in late Q4 2026 or early 2027. Full-year 2026 revenue guidance was raised to $1.595–$1.605 billion, and Adjusted EBITDA guidance of about $65 million was reaffirmed; guidance excludes the Personalis transaction.

No articles ingested yet for Tempus AI. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.